Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 849
- Registration Number
- NCT00078949
- Locations
- 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇺🇸Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
- Conditions
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 34
- Registration Number
- NCT00079079
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT00079040
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix
- Conditions
- First Posted Date
- 2004-03-05
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Registration Number
- NCT00005965
- Locations
- 🇺🇸
Saint Vincent Catholic Medical Center of New York, New York, New York, United States
🇺🇸NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
🇺🇸New York Presbyterian Hospital - Cornell Campus, New York, New York, United States
SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors
- Conditions
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer
- Conditions
- First Posted Date
- 2004-03-01
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00003264
- Locations
- 🇺🇸
Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States
🇺🇸Reading Hospital and Medical Center, Reading, Pennsylvania, United States
🇺🇸St. Francis Medical Center, Trenton, New Jersey, United States
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00016367
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2013-09-02
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT00022308
- Locations
- 🇺🇸
Riverview Medical Center - Booker Cancer Center, Red Bank, New Jersey, United States
🇺🇸Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin
- Conditions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- The Christie NHS Foundation Trust
- Registration Number
- NCT00022178
- Locations
- 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1800
- Registration Number
- NCT00003240
- Locations
- 🇬🇧
Middlesex Hospital- Meyerstein Institute, London, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.